zinc finger protein 638Genealiases: NP220 · ZFML · Zfp638
Q-omics provides the consensus-scored ZNF638 profile across patient tissues and cancer cell-line models. ZNF638 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF638 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ZNF638 protein abundance shows 32,037 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where ZNF638 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF638 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF638 survival associations across molecular data types. ZNF638 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (10) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF638 RNA expression–survival associations across cancer types. High ZNF638 expression shows unfavorable associations in ACC, UVM, KICH and KIRP, but favorable associations in KIRC and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF638 RNA expression.
This table summarizes ZNF638 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF638. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF638 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and CHOL. The HNSC box plot shows higher ZNF638 RNA expression in tumor versus normal tissue (log2 FC = +0.517, t-test p < 0.001).
This table shows molecular features associated with ZNF638 in patient tissues and cancer cell lines. In patient samples, ZNF638 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF638 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
